Market News & Trends
Salix Pharmaceuticals to Acquire Oceana Therapeutics for $300 Million
Oceana Therapeutics LLC, a privately owned global company focused on commercializing best-in-class specialty therapeutics, recently announced it has entered into a definitive agreement for the…
11/15/2011
Lundbeck & Otsuka Enter Long-Term CNS Agreement, Deal Has $1.8-Billion Potential Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S recently announced they have entered into…
Accentia Biopharmaceuticals to Sell Analytica for $10 Million
Accentia Biopharmaceuticals, Inc. recently announced it has entered into a series of agreements to strengthen its financial position, improve its balance sheet, and support ongoing…
11/8/2011
Gateway Analytical Growth Demands Move to a Larger Facility Gateway Analytical recently announced the company will move to a larger facility at 5316 William Penn…
CoreRx Adds Precision Powder Microdosing System to its Development Capabilities
CoreRx recently announced it has further enhanced its offering by adding an Xcelodose precision powder microdosing system to its Product Development capabilities in response to…
Evonik Acquires Pharmaceuticals Business of SurModics
Evonik Industries AG recently announced it has reached an agreement to acquire the Pharmaceuticals business of SurModics, Inc. headquartered in Eden Prairie, MN. The signing…
Gateway Analytical Growth Demands Move to a Larger Facility
Gateway Analytical recently announced the company will move to a larger facility at 5316 William Penn Highway, Gibsonia, PA, after outgrowing the current laboratory and…
Gilead Submits NDA to FDA for Quad Tablet
Gilead Sciences, Inc. recently announced it has submitted an NDA to the US FDA for marketing approval of the Quad, a complete single-tablet regimen of…
GSK to Use Alnylam Pharmaceuticals' RNAi Technology for Vaccine Production
Alnylam Pharmaceuticals, Inc. recently announced it has formed a collaboration with GSK focused on Alnylam's VaxiRNA technology for certain GSK vaccine products, including influenza. VaxiRNA…
Repligen Buys Novozymes Biopharma Unit
Repligen Corporation recently announced the execution of a definitive agreement to acquire the business of Novozymes Biopharma Sweden AB in a cash transaction of $22.7…
Biogen Idec & Portola Pharmaceuticals Strike $553-Million Deal
Biogen Idec and Portola Pharmaceuticals, Inc. recently announced they have entered into an exclusive, worldwide collaboration and license agreement under which both companies will develop…
Bio-Images & Medimetrics Partner to Deliver Next-Generation Smart Pill Technology
Bio-Images Research and Medimetrics Personalized Drug Delivery recently announced a partnership to introduce the IntelliCap to the global pharmaceutical industry as a clinical research tool.…
Encap Drug Delivery & Lena Nanoceutics to Develop Nano-Capsule Technology
Encap Drug Delivery and Lena Nanoceutics recently announced a collaboration agreement to develop a new drug delivery technology (Nano-Capsules) that combines Lena's proprietary nanoparticle engineering…
11/01/2011
Activartis Develops Cancer Vaccine in Phase II, Seeks Partner Activartis GmbH (formerly Trimed Biotech GmbH) recently announced it is developing a cancer immunotherapy concept that…
3M DDS Announces New VP & General Manager
3M Drug Delivery Systems recently announced the appointment of James Ingebrand as the new Vice President and General Manager after the retirement of his predecessor,…
Activartis Develops Cancer Vaccine in Phase II, Seeks Partner
Activartis GmbH (formerly Trimed Biotech GmbH) recently announced it is developing a cancer immunotherapy concept that is currently in Phase II clinical trials. Initially directed…
Acton Pharmaceuticals Announces License Agreement for Nasal Aerosol
Acton Pharmaceuticals, Inc. recently announced it has completed a licensing agreement with Sanofi US for prescription NASACORT HFA (triamcinolone acetonide) Nasal Aerosol for the treatment…
10/25/2011
Abbott to Separate Into Two Leading Companies Abbott recently announced it plans to separate into two publicly traded companies, one in diversified medical products, and…
Abbott to Separate Into Two Leading Companies
Abbott recently announced it plans to separate into two publicly traded companies, one in diversified medical products, and the other in research-based pharmaceuticals. The diversified…
Evonik Launches EUDRAGIT E PO ReadyMix
Essen, Germany-based Evonik Industries recently announced it has launched EUDRAGIT E PO ReadyMix, a ready-to-use powder blend for taste-masking and moisture protection coatings of pharmaceutical…
